LEADER (trial)
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
Definition
The first GLP-1 cardiovascular outcomes trial to show a MACE reduction: 9,340 adults with type 2 diabetes plus established CVD or high risk, liraglutide against placebo over a median 3.8 years (Marso 2016 NEJM, PMID 27295427). MACE HR 0.87, P=0.01. It established the class as cardioprotective before SUSTAIN-6 confirmed it.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Major trials
Where the evidence lives
- LEADER trial deep-dive
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers